SEI Investments’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$94.6M Buy
619,274
+54,262
+10% +$8.32M 0.09% 243
2025
Q4
$77.9M Buy
565,012
+44,921
+9% +$5.88M 0.08% 267
2025
Q3
$66.7M Buy
520,091
+8,344
+2% +$1.02M 0.07% 273
2025
Q2
$61.9M Sell
511,747
-58,288
-10% -$6.57M 0.07% 295
2025
Q1
$63.5M Buy
570,035
+38,150
+7% +$4.06M 0.08% 275
2024
Q4
$51.8M Buy
531,885
+16,519
+3% +$1.76M 0.07% 309
2024
Q3
$59.3M Sell
515,366
-54,586
-10% -$6.19M 0.08% 279
2024
Q2
$60.7M Sell
569,952
-2,937
-0.5% -$295K 0.09% 248
2024
Q1
$55.4M Sell
572,889
-37,859
-6% -$3.88M 0.08% 265
2023
Q4
$61.7M Buy
610,748
+4,431
+0.7% +$428K 0.1% 209
2023
Q3
$61.8M Sell
606,317
-29,231
-5% -$2.97M 0.11% 173
2023
Q2
$64.1M Sell
635,548
-20,539
-3% -$2.05M 0.11% 168
2023
Q1
$60.4M Buy
656,087
+26,329
+4% +$2.3M 0.11% 179
2022
Q4
$57.1M Buy
629,758
+29,524
+5% +$2.49M 0.13% 158
2022
Q3
$45.6M Sell
600,234
-44,644
-7% -$3.7M 0.1% 208
2022
Q2
$54.6M Sell
644,878
-25,517
-4% -$2.24M 0.12% 158
2022
Q1
$58.8M Buy
670,395
+8,044
+1% +$696K 0.12% 164
2021
Q4
$57.9M Sell
662,351
-217,716
-25% -$18.1M 0.11% 196
2021
Q3
$72M Buy
880,067
+34,275
+4% +$3.08M 0.15% 130
2021
Q2
$77.1M Buy
845,792
+37,401
+5% +$3.33M 0.17% 108
2021
Q1
$70.3M Buy
808,391
+20,672
+3% +$1.86M 0.18% 102
2020
Q4
$74.4M Sell
787,719
-7,618
-1% -$666K 0.19% 88
2020
Q3
$69.2M Sell
795,337
-57,503
-7% -$4.98M 0.2% 89
2020
Q2
$74.5M Sell
852,840
-296,114
-26% -$25.6M 0.23% 73
2020
Q1
$94.7M Sell
1,148,954
-124,196
-10% -$11.1M 0.35% 49
2019
Q4
$121M Buy
1,273,150
+63,402
+5% +$5.69M 0.36% 42
2019
Q3
$105M Sell
1,209,748
-27,093
-2% -$2.43M 0.27% 55
2019
Q2
$113M Sell
1,236,841
-184,989
-13% -$15.7M 0.37% 41
2019
Q1
$123M Sell
1,421,830
-33,107
-2% -$2.66M 0.41% 41
2018
Q4
$112M Buy
1,454,937
+30,670
+2% +$2.39M 0.4% 40
2018
Q3
$110M Sell
1,424,267
-188,792
-12% -$14M 0.4% 41
2018
Q2
$109M Buy
1,613,059
+60,288
+4% +$4.16M 0.37% 40
2018
Q1
$112M Buy
1,552,771
+291,584
+23% +$22.2M 0.43% 37
2017
Q4
$94.9M Buy
1,261,187
+23,564
+2% +$1.78M 0.33% 52
2017
Q3
$95.2M Sell
1,237,623
-426,862
-26% -$32.2M 0.34% 52
2017
Q2
$124M Buy
1,664,485
+419,335
+34% +$29.7M 0.5% 23
2017
Q1
$82.9M Buy
1,245,150
+97,649
+9% +$6.51M 0.36% 44
2016
Q4
$74.9M Buy
1,147,501
+104,059
+10% +$6.75M 0.36% 45
2016
Q3
$73.8M Buy
1,043,442
+345,732
+50% +$25.2M 0.38% 46
2016
Q2
$51.6M Sell
697,710
-3,304
-0.5% -$228K 0.31% 66
2016
Q1
$45.5M Buy
701,014
+50,914
+8% +$3.46M 0.28% 79
2015
Q4
$50.1M Buy
650,100
+297,533
+84% +$23.6M 0.31% 62
2015
Q3
$29M Buy
352,567
+17,412
+5% +$1.55M 0.27% 86
2015
Q2
$29.5M Buy
335,155
+3,803
+1% +$349K 0.27% 95
2015
Q1
$29.3M Buy
331,352
+3,162
+1% +$280K 0.25% 96
2014
Q4
$27.2M Buy
+328,190
New +$27.2M 0.24% 106

Other funds holding NVS

SEI Investments's NVS Position: Q1 2026 in Review

SEI Investments increased its Novartis (NVS) stake by 9.6% in Q1 2026, buying an estimated $8.32M and bringing the position to 619,274 shares worth $94.6M. The position accounts for 0.09% of the portfolio, ranked #243.

SEI Investments first reported a position in NVS in Q4 2014 and has held it in 46 quarters since. The position peaked at $124M in Q2 2017. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • SEI Investments held 619,274 shares of Novartis worth $94.6M as of Q1 2026.
  • SEI Investments bought 54,262 Novartis shares in Q1 2026, an estimated $8.32M.
  • Novartis made up 0.09% of SEI Investments's portfolio in Q1 2026, its #243 holding.
  • SEI Investments first reported a position in Novartis in Q4 2014 and has held it in 46 quarters since.
  • SEI Investments's Novartis position peaked at $124M in Q2 2017.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.